
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
9.97 (USD) • At close May 9, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | BioCryst Pharmaceuticals, Inc. |
Symbool | BCRX |
Munteenheid | USD |
Prijs | 9.97 |
Beurswaarde | 2,086,222,500 |
Dividendpercentage | 0% |
52-weken bereik | 5.06 - 11.11 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jon P. Stonehouse |
Website | https://www.biocryst.com |
An error occurred while fetching data.
Over BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)